EU-MSC2-meeting report

RETHRIM investigates the use of Mesenchymal Stromal Cells (MSC) for the treatment of Graft versus Host Disease. In this affliction which can occur as a side effect of hematopoietic stem cell transplantation the body of the stem cell recipient is attacked by the stem cell graft ou acheter cialis pas cher. The immune system within the patient goes haywire and needs to be controlled. MSC can be used to dampen the immune response especially in patients that do not respond to more conventional immune dampening treatments such as steroids.

The immune suppressive properties of MSC can be used in a number of diseases in which the immune system needs to be controlled more rigorously. Examples are diabetes in which the body attacks it’s own insuline producing cells or Crohn’s disease in which the immune system reacts too strongly affecting the patients intestines.

A number of research groups within the European Union work on MSC, investigating the potential use of these cells to treat a variety of diseases. To learn from each others expertise, exchange ideas and to further research on MSC across Europe these research groups met a while ago. The members of RETHRIM were present at this meeting to share their knowledge on clinical trial using MSC. Interested in the results of that meeting? See the report of the EU-MSC2 meeting below.